American College Of Surgeons - Inspiring Quality: Highest Standards, Better Outcomes

CMS to Offer MIPS Credit to Clinicians Participating in COVID-19 Clinical Trials

The Centers for Medicare and Medicaid Services (CMS) is now offering Merit-based Incentive Payment System (MIPS) credit to clinicians who participate in a clinical trial and report clinical information by attesting to the new COVID-19 Clinical Trails improvement activity (IA). CMS believes this action will provide important data that will help drive improvement in patient care and development of innovative best practices that could help stop the spread of COVID-19 and contribute to scientific research related to the COVID-19 pandemic.

To receive credit for the new COVID-19 Clinical Trials IA, clinicians must attest that they participate in a COVID-19 clinical trial using a drug or biological product to treat a patient with a COVID-19 infection and report their findings through a clinical data repository or clinical data registry for the duration of the study. CMS offers flexibility in the type of clinical trial that meets the requirements for this IA, which carries a high weight in the IA performance category. Because the activity is considered high weight, those who attest to the COVID-19 Clinical Trials activity will automatically earn half of the total credit required to earn the maximum score in the IA performance category, which is 15 percent of their MIPS final score.

CMS recently released a press release that provides more details about the addition of this new IA in the MIPS program. Further questions can be directed to